GlassScriptPhysician profile
Manuel R Cabrera
NPI 1932271327
$5,528.36
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,042 · 2020: $1,205 · 2021: $2,263 · 2022: $18.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,317.86 | 2019-2021 | |
| Glaxosmithkline, LLC. | $1,018.47 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $743.91 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $461.40 | 2019-2021 | |
| Insmed, INC. | $350.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $336.56 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.65 | 2019-2021 | |
| Novo Nordisk INC | $137.95 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $125.62 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $122.07 | 2019-2021 | |
| Boston Scientific Corporation | $116.58 | 2019-2021 | |
| Genzyme Corporation | $74.85 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $57.68 | 2020-2021 | |
| Genentech USA, INC. | $57.22 | 2019-2021 | |
| Amarin Pharma, INC. | $54.44 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.27 | 2019-2021 | |
| Amgen INC. | $38.50 | 2019 | |
| Mylan Specialty L.P. | $37.91 | 2019 | |
| Circassia INC. | $32.09 | 2019 | |
| Optinose US, INC. | $31.21 | 2021 | |
| Arbor Pharmaceuticals, INC. | $21.64 | 2021 | |
| Abbvie INC. | $21.06 | 2021 | |
| Merck Sharp & Dohme LLC | $20.87 | 2021 | |
| Allergan, INC. | $19.90 | 2019 | |
| Intercept Pharmaceuticals, INC. | $18.20 | 2021 | |
| Redhill Biopharma INC. | $15.77 | 2021 | |
| Electromed, INC. | $13.92 | 2021 | |
| Phadia US INC. | $12.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.